Immunological evaluation in nonhuman primates of formulations based on the chimeric protein P64k-domain III of dengue 2 and two components ofNeisseria meningitidis

The main problem in the development of successful vaccines against dengue based on recombinant proteins is the necessity to use potent adjuvants to reach a proper functional immune response. Our group reported the expression, characterization and immunological evaluation of the recombinant protein P...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2009-02, Vol.27 (7), p.995
Main Authors: Valdés, Iris, Hermida, Lisset, Martín, Jorge, Menéndez, Tamara, Gil, Lázaro, Lazo, Laura, Castro, Jorge, Niebla, Olivia, López, Carlos, Bernardo, Lídice, Sánchez, Jorge, Romero, Yaremis, Martínez, Rafael, Guzmán, María G, Guillén, Gerardo
Format: Article
Language:English
Subjects:
Aluminum
Bacteriology
Dengue fever
Immune response
Immunization
Immunology
Infections
Laboratory animals
Meningitis
Monkeys & apes
Proteins
Studies
Vaccines
Vector-borne diseases
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The main problem in the development of successful vaccines against dengue based on recombinant proteins is the necessity to use potent adjuvants to reach a proper functional immune response. Our group reported the expression, characterization and immunological evaluation of the recombinant protein PD5, which contains the domain III of the Envelope protein from dengue 2 virus fused to the carrier protein P64k. This construct completely protected monkeys against viral challenge when the Freund's adjuvant was employed. Therefore, to define suitable formulations for human use, the present work relies on the evaluation of PD5, produced with a high purity and under GMP conditions, when formulated either with outer membrane vesicles (OMV) or the serogroup A capsular polysaccharide (CPS-A) fromNeisseria meningitidis, both adsorbed on aluminium hydroxide. The antibody response to the formulation containing the CPS-A was clearly superior to that of the formulation with OMV. The experiment ofin vivoprotection supported this evidence, since only the group immunized with PD5 and CPS-A was partially protected upon viral challenge. This is the first study in which the polysaccharide A ofN. meningitidisis successfully employed as adjuvant for viral antigens.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2008.11.106